Amaro Therapeutics, Inc.
Who We Are
Amaro Therapeutics is pioneering small-molecule agonists of extra-oral bitter taste receptors to treat diseases driven by metabolic dysfunction, chronic inflammation, and cellular senescence.
Bitter taste receptors (TAS2Rs) are highly conserved GPCRs found across nearly all tissues, including the gastrointestinal tract, lungs, cardiovascular system, immune cells, and senescent cells. Beyond their sensory role, TAS2Rs regulate:
-
Gut hormone secretion influencing appetite and glucose control
-
Innate immune activation in respiratory tissues
-
Smooth muscle tone in the heart, vasculature, uterus, and airways
We view extra-oral TAS2Rs as multi-system integrators capable of simultaneously modulating endocrine, metabolic, and immune pathways — and, as emerging evidence shows, senescence biology.
Our Platform
Amaro’s discovery platform unlocks the therapeutic potential of chemoreceptors — particularly the bitter taste receptor (TAS2R) family — as novel drug targets. We combine over a decade of preclinical and clinical experience with proprietary tools to identify, optimize, and advance small-molecule agonists that restore metabolic balance, regulate immune function, and address cellular aging.
Our platform is intended to integrate:
-
Our proprietary computational models of all 25 TAS2R to identify novel agonists with optimized selectivity and pharmacokinetics with
-
Tissue-specific TAS2R activation assays and
-
In vivo disease models validating therapeutic potential in high-value indications such as obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH)
This integrated approach generates IP at every stage — from novel compounds to therapeutic applications — creating a defensible, scalable pipeline targeting high-impact metabolic diseases of aging.
